POSITRON CORP - POSC STOCK NEWS

Positron Corporation (POSC) welcomes a prominent cardiovascular practice in Pennsylvania as a new customer utilizing the Attrius PET System and services. The company offers a dedicated PET scanner optimized for nuclear cardiology, providing robust high-resolution images and accurate measurements of absolute blood flow. Positron's Lease to Own Program offers a complete package of the Attrius PET System and full scope Clinical & Technical Services for one monthly price for five years, with zero upfront capex expense. The company expects to enter additional lease to own/services agreements with other interested parties.

Positron welcomes a prominent cardiovascular practice in California as a new customer utilizing Positron's Attrius PET System and services. The company anticipates entering five more Attrius Lease to Own/Services agreements by year's end. Positron's PET Lease to Own & Services Program offers a complete package with zero upfront capex expense, providing a viable operational model for nuclear imaging PET practices. The company aims to provide hospitals and private practices with the best technology, services, and solutions to meet customer needs.

Positron Corporation to begin clinical study of Affinity PET-CT imaging device with Ochsner Clinic Foundation

Positron Corporation (POSC) Announces Business Cooperative Partnership and Acquisition of PET Imaging Systems Inventory

Positron Corporation (OTC: POSC) has entered a Clinical Study/Research Agreement with Ochsner Clinic Foundation for its new Affinity™ PET-CT 4D device. This agreement facilitates the collection of safety and efficacy data, crucial for obtaining an Investigational Device Exemption (IDE) from the FDA. The independent Institutional Review Board has approved all study procedures, allowing preparations for patient scans to begin post-IDE approval. The company aims for completion of the clinical study and FDA certification within 60 days, marking a significant step toward commercialization.

Positron Corporation (OTC: POSC) announces a collaboration with Dr. Robert Bober and Ochsner Health for a clinical study of its new Affinity PET-CT 4D imaging device. This FDA-compliant study, commencing mid-January 2023, aims to evaluate the device's image quality and performance in cardiac PET imaging. Dr. Bober's leadership is pivotal for gathering empirical data essential for marketing the system. Following completion and FDA 510k certification, Positron intends to commercialize the device in Q1 2023, targeting nuclear cardiology and oncology markets.

Positron Corporation (OTC: POSC) has announced the purchase of its first Affinity PET-CT system from Neusoft Medical Systems, which is currently in transit to the U.S. for validation. This marks a crucial step in launching the device, aimed at cardiac and oncology imaging. The company plans to reveal details about participating hospitals and expects to submit a 510K application to the FDA soon. President Adel Abdullah highlighted the excitement among industry partners for the upcoming validation studies, set to begin in September and conclude by November 2022.

Positron Corporation (OTC: POSC) announced the appointment of Christopher Reilly to lead its PET-CT Services and Systems Sales. With over 30 years of experience in SPECT imaging, Reilly aims to facilitate the transition from SPECT to PET imaging for hospitals and cardiology practices. The company will validate its new PET-CT device in collaboration with a leading healthcare organization over the next three months. President Adel Abdullah expressed confidence in Reilly's expertise, which is expected to support Positron's sales and marketing initiatives as it prepares to launch its new product.